2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Huntsman Cancer Institute at the University of Utah is a nationally recognized research center and treatment hospital in Salt Lake City. We are the only National Cancer Institute-designated Comprehensive Cancer Center in the Mountain West and serve patients with all types of cancer from Utah, Idaho, Montana, Nevada, and Wyoming. In 2021, we opened the region’s first proton therapy center. We manage the Utah Population Database, the largest genetic database in the world. More genes for inherited cancers have been discovered at our institution than any place in the world, including genes for melanoma and breast, ovarian, colon, head, and neck cancers.
November 11, 2024
Video
Douglas W. Sborov, MD, MS, discusses long-term treatment outcomes for patients with myeloma who received CAR T-cell therapy vs another treatment option.
October 31, 2024
Article
Results of the TALAPRO-2 trial showed that a novel prostate cancer therapy has a higher overall survival rate compared to the standard of care drug alone.
October 28, 2024
Article
Douglas W. Sborov, MD, MS, discusses where ide-cel and cilta-cel each fit into the myeloma treatment paradigm.
October 17, 2024
Article
Cabozantinib plus atezolizumab did not produce superior OS outcomes vs a second novel hormonal therapy in metastatic castration-resistant prostate cancer.
September 13, 2024
Article
Scientists at Huntsman Cancer Institute at the University of Utah, have made a significant breakthrough in predicting the prognosis of triple-negative breast cancer.
July 26, 2024
Article
Michelle Mendoza, PhD, and Jeffrey Weiss, PhD, received a $2.6 million grant from the NIH to research how tension in lung tissue affects the growth and distribution of tumors.
July 23, 2024
Article
Women with severe endometriosis are 10 times more likely to get ovarian cancer, compared to women who do not have the disease.
June 21, 2024
Article
Three Huntsman Cancer Institute researchers have recently been recognized for their work as outstanding faculty members at the University of Utah.
June 11, 2024
Article
Benjamin L. Maughan, MD, PharmD, highlights ongoing research regarding the role of cytoreductive nephrectomy and targeted therapies in RCC.
June 06, 2024
Article
Benjamin L. Maughan, MD, PharmD, discusses the implications of immuno-oncology and TKI agent combinations in clear cell and non–clear cell RCC.
May 06, 2024
Article
In a recent study, researchers at Huntsman Cancer Institute found a trend in families with male infertility: an increased risk of certain cancers.
May 01, 2024
Article
Neli Ulrich, PhD, MS, of Huntsman Cancer Institute, has been awarded the 2024 Governor’s Medal for Science and Technology.
April 05, 2024
Article
Gita Suneja, MD, MS, has been named the senior director of Programs to Enhance Diversity at Huntsman Cancer Institute.
April 03, 2024
Video
Sagar Patel, MD, discusses the utility of the Orca-T platform in patients with hematologic malignancies, highlighting the platform's safety.
April 01, 2024
Video
Elizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.
March 28, 2024
Article
Huntsman Cancer Institute at the University of Utah received $75 million from the Utah Legislature toward a cancer research and academic building.
March 26, 2024
Article
Neeraj Agarwal, MD, FASCO, discusses unmet needs across the prostate cancer spectrum and ongoing trials investigating agents in earlier settings.
March 25, 2024
Video
Experts on bladder cancer discuss exciting new agents and treatment strategies and where they can potentially fit into urothelial cancer treatment paradigms.
March 25, 2024
Video
Focusing on metastatic urothelial carcinoma, the panel discusses the role of chemotherapy and outlines treatment sequencing approaches.
March 18, 2024
Video
Evan Y. Yu, MD, provides insights on treatment approaches for patients with metastatic urothelial carcinoma in the second line and beyond.